PSMA2 and Alzheimer disease: Specifically, we found an increase in the proportion (42.0% vs 54.0%; p = 0.002) and dose (30.6 ± 15.4 vs 41.9 ± 24.7 mg/d of fluoxetine; p < 0.001) of prescribed AD together with an increase in the proportion of AP (52.7% vs 62.4%; p = 0.012), anticonvulsants (2.7% vs 19.0%; p < 0.001) and alpha-2 adrenergic antagonists (1.3% vs 5.8%: p = 0.002) prescribed.